Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.
Saved in:
| Title: | Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials. |
|---|---|
| Authors: | Montalban X; Department of Neurology, Centre d'Esclerosi Múltiple de Catalunya, Hospital Universitario Vall d'Hebron, Barcelona, Spain. Electronic address: xavier.montalban@cem-cat.org., Vermersch P; University Lille, Inserm U1172 LilNCog, Centre Hospitalier Universitaire de Lille, Lille, France., Arnold DL; NeuroRx Research, Montreal, QC, Canada; Montreal Neurological Institute, Montreal, QC, Canada., Bar-Or A; Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Cree BAC; Department of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA., Cross AH; Section of Multiple Sclerosis and Neuroimmunology, Washington University School of Medicine, St Louis, MO, USA., Kubala Havrdova E; General University Hospital, Charles University, Prague, Czech Republic., Kappos L; Departments of Headorgans, Spine and Neuromedicine, Clinical Research, and Biomedical Engineering, Research Center for Clinical Neuroimmunology and Neuroscience, University Hospital Basel, University of Basel, Basel, Switzerland., Stuve O; Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX, USA., Wiendl H; Department of Neurology with Institute of Translational Neurology, University Hospital, Münster, Germany., Wolinsky JS; Department of Neurology, McGovern Medical School, University of Texas Health Science Center, Houston, TX, USA., Dahlke F; Impulze, Zürich, Switzerland., Le Bolay C; Merck Santé, an affiliate of Merck KGaA, Lyon, France., Shen Loo L; EMD Serono, an affiliate of Merck KGaA, Billerica, MA, USA., Gopalakrishnan S; Merck KGaA Healthcare, Darmstadt, Germany., Hyvert Y; Merck KGaA Healthcare, Darmstadt, Germany., Javor A; Ares Trading, an affiliate of Merck KGaA, Eysins, Switzerland., Guehring H; Merck KGaA Healthcare, Darmstadt, Germany., Tenenbaum N; EMD Serono, an affiliate of Merck KGaA, Billerica, MA, USA., Tomic D; Ares Trading, an affiliate of Merck KGaA, Eysins, Switzerland. |
| Corporate Authors: | evolutionRMS investigators |
| Source: | The Lancet. Neurology [Lancet Neurol] 2024 Nov; Vol. 23 (11), pp. 1119-1132. Date of Electronic Publication: 2024 Sep 19. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 101139309 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-4465 (Electronic) Linking ISSN: 14744422 NLM ISO Abbreviation: Lancet Neurol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
